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Abstract
Background: Associations of bisphenol A and phthalates with chronic disease health outcomes are increasingly
being investigated in epidemiologic studies. The majority of previous studies of within-person variability in urinary
bisphenol A and phthalate metabolite concentrations have focused on reproducibility over short time periods.
Long-term reproducibility data are needed to assess the potential usefulness of these biomarkers for prospective
studies, particularly those examining risk of diseases with long latency periods. Low within-person reproducibility
may attenuate relative risk estimates and reduce statistical power to detect associations with disease. Therefore, we
assessed within-person reproducibility of bisphenol A, eight phthalate metabolites, and phthalic acid in spot urine
samples over 1 to 3 years among women enrolled in two large cohort studies.
Methods: Women in the Nurses’ Health Study and Nurses’ Health Study II provided two spot urine samples, 1 to
3 years apart (n=80 women for analyses of bisphenol A; n=40 women for analyses of phthalate metabolites; n=34
women for analyses of phthalic acid). To measure within-person reproducibility, we calculated Spearman rank
correlation coefficients and intraclass correlation coefficients for creatinine-adjusted concentrations of bisphenol A,
phthalate metabolites, and phthalic acid.
Results: Over 1 to 3 years, within-person variability of bisphenol A was high relative to total variability (intraclass
correlation coefficient=0.14) and rankings of bisphenol A levels between time-points were weakly correlated
(Spearman correlation=0.19). Seven of the eight phthalate metabolites and phthalic acid demonstrated moderate
within-person stability over time (Spearman correlation or intraclass correlation coefficient=0.39-0.55). Restricting
analyses to first-morning urine samples did not alter results.
Conclusions: Single measurements of bisphenol A in spot urine samples were highly variable within women over 1 to
3 years, indicating that investigation of associations between a single urinary bisphenol A measurement and disease
risk may be challenging in epidemiologic studies. The majority of urinary phthalate metabolites and phthalic acid
appeared moderately reproducible within women over time, suggesting single measurements may be useful in
epidemiologic studies, although observed relative risks can be substantially attenuated.
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Bisphenol A (BPA) is a man-made chemical used mainly
in the manufacture of polycarbonate plastics and epoxy
resins [1]. BPA-containing plastics and epoxy resins are
used in many items such as containers for foods and
beverages, impact-resistant safety equipment and baby
bottles, toys, coatings inside metal cans, dental compos-
ites and sealants, and in color developer used in certain
types of receipt paper [1,2]. In addition, BPA is present
in the air, soil, and water [2]. Thus, humans may be
exposed to BPA through multiple sources, including the
diet, dermal contact, and inhalation [2].
Esters of phthalic acid, or phthalates, are a class of
man-made chemicals used to produce plastics as well as
other items. Phthalates are found in products such as
floorings, clothing, packaging materials, toys, medical
devices made with polyvinyl chloride (e.g., blood and en-
teral nutrition bags, tubing, catheters), and personal care
products [1]. Since phthalates are not chemically bound to
plastics, they are ubiquitous in the environment. Human
exposure to phthalates occurs through ingestion, inhal-
ation, medical procedures, and dermal absorption [1,3].
BPA and phthalates disrupt the endocrine system [2,4].
Thus, there is great scientific interest in elucidating poten-
tial pathologic effects of human exposure to these chemi-
cals. Given the short half-lives of BPA and phthalates [5,6],
epidemiologic studies examining relations between envir-
onmental exposure to these chemicals and health out-
comes have focused on measurements in urine, rather
than in blood where concentrations are generally low [1].
Also, since phthalates are rapidly metabolized in the body
to their respective hydrolytic monoesters and oxidized
monoesters [1], research studies generally measure urinary
concentrations of phthalate metabolites as biomarkers of
exposure to phthalates. To date, the large majority of
epidemiologic studies of associations of urinary BPA and
phthalate metabolites with risk of chronic conditions in
adults have primarily used cross-sectional study designs.
For example, studies using data from the National Health
and Nutrition Examination Survey have reported modest
associations of urinary BPA with cardiovascular disease
[7], diabetes [8], and hypertension [9] as well as modest to
strong associations of urinary phthalate metabolites with
diabetes [10], endometriosis and uterine leiomyomata
[11,12], and poor pulmonary function [13]. Few prospect-
ive studies have examined the relation of urinary BPA
and phthalate metabolites with risk of chronic disease
in adults, although one study observed a borderline-
significant increased risk of incident coronary artery dis-
ease over 11 years with increasing BPA concentration
measured in spot urine samples (odds ratio=1.11 per
4.6 ng/mL increase in BPA, p=0.06) [14].
Investigation of disease associations in prospective
studies is the next step for this area of research.
However, since many epidemiologic studies lack resources
to collect multiple urine samples per study participant,
knowledge of long-term within-person reproducibility of
urinary BPA and phthalate metabolites is critical to deter-
mine whether a single measurement adequately reflects
longer-term exposures. Exposures with low within-person
reproducibility may attenuate relative risks and reduce
statistical power to detect associations with disease [15].
Most studies examining reproducibility of urinary BPA
and phthalate metabolites in adults have focused on short
time periods (i.e., 2 days to 3 months) [16,17], which may
not be relevant for studies examining risk of diseases with
long latency periods. Four studies [18-21] that evaluated
reproducibility of urinary BPA or phthalate metabolites in
adults over a period longer than 3 months focused on
adults aged ≤55 years attending a fertility clinic or preg-
nant women, among whom patterns of exposure to BPA
and phthalates may be different than among older adults.
Therefore, we examined within-person reproducibility of
BPA, eight phthalate metabolites, and phthalic acid (PA)
among women aged 33 to 78 who donated two spot urine
samples 1 to 3 years apart.
Methods
Study design
The Nurses’ Health Study (NHS) began in 1976 when
121,700 female registered nurses, aged 30 to 55 years
and living in 11 U.S. states, responded to a mailed
questionnaire about their health and lifestyle [22]. In
1989, a second cohort, the NHSII, was established
when 116,430 female registered nurses, aged 25 to
42 years and living in 14 U.S. states, responded to a
similar questionnaire.
Details of the NHS and NHSII urine collections were
published previously [23]. Briefly, in 2000 to 2001, 18,473
NHS participants were asked to collect a first morning
urine sample in a polypropylene container. Women
shipped the urine sample with an icepack by overnight
courier to our laboratory, where it was aliquoted into poly-
propylene cryovials without preservative and stored in
liquid nitrogen freezers. In 2002 to 2003, 2,005 of these
women provided a second urine sample using the same
collection and shipment methods as the initial collection.
In 1996 to 1999, 18,521 NHSII participants who had
not used oral contraceptives or been pregnant or lactat-
ing within 6 months were asked to provide a first morn-
ing urine sample; 304 of these women, who were not
planning to be pregnant or lactating over the next
3 years, provided an additional urine sample in 1998–
2000. Collection and shipment methods were identical
to those described above.
To evaluate reproducibility of BPA, phthalate metabo-
lites, and PA, we analyzed urine samples donated 1 to
3 years (mean 2 years) apart by study participants
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(n =2 samples per participant). BPA analyses included
20 NHS and 60 NHSII participants, phthalate metabolite
analyses included 40 NHS participants, and PA analyses
included 34 NHS participants. Participants provided im-
plied consent by returning the questionnaires and urine
samples. The Institutional Review Board of Brigham and
Women’s Hospital approved this study.
Laboratory methods
We measured BPA, eight phthalate metabolites, and
PA in the spot urine samples using modifications of
established methods [24,25]. The eight phthalate metab-
olites were: 1) monoethyl phthalate (MEP), the primary
metabolite of diethyl phthalate; 2) monoisobutyl phthal-
ate (MiBP) and 3) mono-n-butyl phthalate (MnBP), pri-
mary metabolites of dibutyl phthalates; 4) monobenzyl
phthalate (MBzP), the primary metabolite of benzylbutyl
phthalate; 5) mono-2-ethylhexyl phthalate (MEHP), the
primary metabolite of di-2-ethylhexyl phthalate (DEHP);
and three secondary metabolites of DEHP, including
6) mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP),
7) mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), and
8) mono-(2-ethyl-5-carboxy-pentyl) phthalate (MECPP).
We spiked 200 μL urine with 20 μL of a mixture of
isotopically labeled phthalate metabolites (Table 1) and
BPA-
13C12, to be used as internal standards followed by
treatment with β-glucuronidase and sulfatase at 37°C for
90 minutes. After acidification with 50 μL glacial acetic
acid, extraction with 1.1 mL methyl tertiary butyl ether
was performed. Half of the ether phase was dried with
nitrogen for phthalate analysis while the second half of
the ether phase was dried for BPA analysis.
The first half of the extract was reconstituted in 125 μL
0.1% formic acid in methanol/water (1:1) for phthalates
and analyzed by orbitrap liquid chromatography-mass
spectrometry (model Exactive; Thermo Electron, Waltham,
Massachusetts); 0.02 mL were injected onto a BETASIL
Phenyl column (150 × 2.1 mm, 3 μm, Thermo, Waltham,
Massachusetts) with mobile phase A (0.1% formic acid in
water) and mobile phase B (0.1% formic acid in aceto-
nitrile) at a flow rate of 0.35 mL per minute with the
following gradient: 75% A/25% B at 0 minutes, increased
to 60% A/40% B at 6 minutes, then 40% A/60% B at 12
minutes and kept at the same ratio for 2 minutes, then at
14.1 minutes changed back to initial condition and equi-
librium for 4 minutes. Mass detection was carried out in
negative electrospray ionization mode using exact masses
as detailed in Table 1. Data acquisition and analysis was
performed using Xcalibur software (Thermo). Detection
of the analytes was set within 10 parts per million of the
calculated mass.
13C4-MBP was used as the internal stand-
ard for MECPP, MEHHP, MiBP, and MnBP since their re-
tention times were similar; otherwise the isotope of the
respective analyte was used as internal standard. Limits of
detection were 0.1-1.0 ng/mL (Table 1).
BPA was analyzed by liquid chromatography-tandem
mass spectrometry (model TSQ Ultra; Thermo Electron)
after dansylation. The dried second fraction from above
and BPA calibrators were treated with 75 μLo ft r i -
ethylamine (2% volume to volume in dichloromethane)
and 125 μL dansyl chloride (4 mg/mL in dichloromethane).
Table 1 Parameters of phthalate metabolites and phthalic acid for orbitrap mass spectrometry quantification
Compound name Ionization mode m/z tR (minutes) LOD (ng/mL)
Monoethyl phthalate (MEP) -ESI 193.05008 6.9 2
Mono-n-butyl phthalate (MnBP) -ESI 221.08138 10.8 0.4
Monoisobutyl phthalate (MiBP) -ESI 221.08138 10.7 0.3
Monobenzyl phthalate (MBzP) -ESI 255.06573 11.4 0.1
Mono-2-ethylhexyl phthalate (MEHP) -ESI 277.14398 12.8 0.5
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) -ESI 293.13890 10.5 0.1
Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) -ESI 291.12325 10.8 0.2
Mono-(2-ethyl-5-carboxy-pentyl) phthalate (MECPP) -ESI 307.11816 10.6 0.2
Phthalic acid (PA) -ESI 165.01858 2.63 0.1
Internal standards
13C4- MEP -ESI 197.06350 6.9
13C4- MnBP -ESI 225.09480 10.8
13C4- MBzP -ESI 259.07915 11.4
13C4- MEHP -ESI 281.15740 12.8
13C4- MEOHP -ESI 295.13666 10.8
PA-d4 -ESI 169.04398 2.63
Abbreviations: --ESI negative electrospray ionization, LOD limit of detection, m/z mass-to-charge ratio, tR retention time.
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was dried under a stream of nitrogen and reconstituted
in 125 μLm e t h a n o l ;2 0μL of the dansylated mixture
was injected onto a Agilent ZORBAX SB-C18 column
(3 × 50 mm, 1.8 μm; Agilent Technologies, Lexington,
Massachusetts) with mobile phase A (0.1% formic acid in
water) and mobile phase B (0.1% formic acid in aceto-
nitrile) at a flow rate of 800 μL per minute with the follow-
ing gradient: 40% A/60% B at 0 minutes, increased to 10%
A/90% B at 10 minutes and kept at the same ratio for 1
minute, then changed back to initial condition at 11.1
minutes and equilibrium for 4 minutes. Mass detection
was carried out in positive electrospray ionization mode
with spray voltage at 3.5 kilovolts, capillary temperature
300°C, and sheath gas (pressure 35 units) and auxiliary gas
(pressure 10 units). The divert valve was set to detector
from 4–15 minutes. Signal acquisition was performed in
selected reaction monitoring mode detecting the transi-
tion of mass-to-charge ratio 695>170 for BPA and 707>
170 for
13C12-BPA. The limit of detection was 0.05 ng/mL.
Urinary creatinine was measured with a Roche-Cobas
Mira Plus clinical chemistry analyzer (Roche Diagnos-
tics, Indianapolis, Indiana) using a kit from Randox
Laboratories (Crumlin, United Kingdom) that is based
on a kinetic modification of the Jaffé reaction with a
lower limit of quantitation of <15 μM/L.
To monitor assay reproducibility, we included repli-
cate blinded quality control samples from three urine
quality control pools among the participant samples to
assess reproducibility of BPA (n= 16 quality control
samples) and phthalate metabolites (n= 8 quality control
samples), and PA (n = 6 quality control samples). Mean
coefficients of variation of BPA, MEP, MiBP, MnBP,
MBzP, MEHP, MEHHP, MEOHP, MECPP, and PA were
12%, 12%, 15%, 10%, 7%, 6%, 5%, 5%, 17%, and 6% at
mean levels of 4, 279, 9, 31, 29, 10, 43, 31, 50, and
53 ng/mL respectively. The mean coefficient of variation
for creatinine was 8% at a mean level of 0.64 mg/ml.
Statistical analysis
To account for potential differences in urine concentra-
tions, we divided BPA, phthalate metabolite, and PA
concentrations by creatinine levels resulting in absolute
excretion units (ng/mg creatinine). Additionally, we
present analyte concentrations in molar units (pmol/mg
creatinine). Summary phthalate metabolite measures (i.e.,
sum of dibutyl phthalates metabolites, sum of DEHP me-
tabolites, and sum of all 8 metabolites) are presented
in molar units only. Values were log-transformed in our
analyses to account for non-normal distribution.
Within-person reproducibility of analyte levels was
assessed using the Spearman rank correlation coefficient
and the intraclass correlation coefficient (ICC), defined
as the between-person variance divided by the sum of
the within- and between-person variances. Variance com-
ponents were estimated using a mixed model with partici-
pant as the random variable. An ICC ≥0.75 indicates
excellent reproducibility, 0.4 to 0.75 indicates fair to good
reproducibility, and <0.4 indicates poor reproducibility
[26]. In additional analyses, we calculated Spearman corre-
lations and ICCs using data from first-morning urine sam-
ples only. Also, for BPA (the study with the largest sample
size), we calculated Spearman correlations and ICCs sep-
arately among women who donated urine samples <25
months apart (N=42 women) and ≥25 months apart
(N=38 women) to explore whether reproducibility was
higher in samples donated closer together in time. During
laboratory analysis of PA study urine samples, one partici-
pant’s second collection measurement could not be
obtained due to a technical error; we retained this partici-
pant’s first collection measurement in ICC calculations to
contribute to the estimate of the between-person variance.
To assess the within-person stability of categories of
analyte levels over time, we created quartile categories
based on analyte distributions at each time point and
cross-classification tables of analyte quartiles at time 1
versus time 2. We calculated weighted kappa statistics
and 95% confidence intervals (CIs) to quantify the agree-
ment between quartile categories defined at each time
point.
Results
Characteristics of urine samples and study participants
at each time point are summarized in Table 2. Although
all women were asked to collect first morning urine
samples, some participants donated spot samples. Over-
all, 92% of NHS samples and 81% of NHSII samples
were first morning urine. The large majority of study
participants were non-smokers at the time of the urine
collections.
Among phthalate metabolites, MEP had the highest
excretion (median 140.5, 5
th to 95
th percentile: 21.0,
894.6 ng/mg creatinine) and MiBP the lowest excretion
(median 3.5, 5
th to 95
th percentile: 0.9-12.0 ng/mg cre-
atinine) (Table 3). The excretion of BPA was the lowest
of all measured analytes (median 2.7, 5
th to 95
th percent-
ile: 0.9-9.2 ng/mg creatinine).
In all samples, as well as first-morning urine samples,
we observed high within-person variability relative to
total variability of BPA (ICC =0.14 and 0.15, respect-
ively) (Table 4). In addition, rankings of BPA excretion 1
to 3 years apart were weakly correlated (Spearman cor-
relation = 0.19 for all samples and 0.23 for first-morning
urine samples). In additional analyses, we separately
evaluated reproducibility of BPA among women who
donated urine samples <25 versus ≥25 months apart.
Within-person variability relative to total variability
remained high among both sub-groups of women, but
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ples closer (ICC=0.23, 95% CI 0.06, 0.60) than further
apart in time (ICC=0.06, 95% CI 0.00, 0.94), although CIs
for the ICCs were wide. Spearman correlations were simi-
lar in these sub-groups (0.16 among samples donated <25
months apart and 0.23 among samples donated ≥25
months apart).
Overall, most phthalate metabolites (MEP, MiBP, MnBP,
MBzP, MEHHP, MEOHP, and MECPP) and PA demon-
strated fair or nearly fair within-person stability over time
(i.e., Spearman correlation or ICC=0.39-0.55) (Table 4).
There was no correlation between rankings of MEHP
measurements 1 to 3 years apart and high within-person
variability in MEHP relative to total variability (Spearman
correlation=0.03, ICC=0.14). Spearman correlations and
ICCs generally were similar or slightly higher when
restricting to first-morning urine samples.
We also evaluated the agreement between quartile cat-
egories defined by the analyte distribution at each time
point. Levels of BPA and MEHP, which had the lowest
Table 2 Characteristics of urine samples and participants in within-person reproducibility analyses
Bisphenol A study Phthalate metabolite study Phthalic acid study
Variable Collection 1 Collection 2 Collection 1 Collection 2 Collection 1 Collection 2
Participants, N 80 80 40 40 34 33
Months between urine collections, %
12 1 0 0
13-18 18 5 6
19-24 33 3 3
25-30 23 34 41
31-36 25 58 50
First morning urine, n (%) 68 (85) 66 (83) 39 (98) 34 (85) 33 (97) 29 (88)
Age, years, mean (range) 48 (33–78) 50 (34–81) 66 (54–78) 69 (56–81) 66 (54–78) 69 (56–81)
White race, n (%) 76 (95) 40 (100) 34 (100)
BMI, kg/m
2, median (10
th-90
th percentile) 25 (21–35) 25 (21–38) 24 (20–30) 23 (20–31) 24 (20–30) 23 (20–30)
Current cigarette smoker, n (%) 2 (3) 1 (1) 2 (5) 1 (3) 1 (3) 1 (3)
Abbreviation: BMI body mass index.
Table 3 Urinary bisphenol A, phthalate metabolite, and phthalic acid excretion distributions after adjustment for
creatinine levels
Analyte Parent
phthalate
Geometric mean Median (5
th -9 5
th percentile)
ng/mg creatinine pmol/mg creatinine ng/mg creatinine pmol/mg creatinine
Bisphenol A NA 2.8 12.1 2.7 (0.9 – 9.2) 12.0 (3.8 – 40.3)
Phthalate metabolite
MEP DEP 135.9 700.7 140.5 (21.0 – 894.6) 724.2 (108.2 – 4611.2)
MiBP DBP 3.6 16.1 3.5 (0.9 – 12.0) 15.6 (4.2 – 54.0)
MnBP DBP 37.0 166.7 36.8 (10.4 – 177.0) 165.8 (46.7 – 797.4)
DBP metabolite sum
a DBP 190.9 177.7 (52.8 – 1157.2)
MBzP BzBP 16.1 62.8 14.3 (4.2 – 96.9) 55.7 (16.3 – 378.4)
MEHP DEHP 5.8 20.8 5.1 (1.5 – 26.0) 18.5 (5.3 – 93.4)
MEHHP DEHP 35.7 121.3 31.7 (8.7 – 162.8) 107.9 (29.5 – 553.8)
MEOHP DEHP 30.7 105.0 25.6 (7.4 – 136.2) 87.7 (25.3 – 466.5)
MECPP DEHP 46.3 150.4 42.5 (15.8 – 214.8) 137.9 (51.4 – 697.4)
DEHP metabolite sum
a DEHP 421.4 361.7 (120.4 – 1520.5)
Total
b NA 1681.3 1566.0 (415.5 – 8687.9)
Phthalic acid NA 88.2 531.1 90.0 (38.5 – 196.1) 542.5 (232.2 – 1181.5)
Abbreviations: BzBP benzylbutyl phthalate, DBP dibutyl phthalates, DEHP di-2-ethylhexyl phthalate, DEP diethyl phthalate, MBzP monobenzyl phthalate, MECPP
mono-(2-ethyl-5-carboxy-pentyl) phthalate, MEHHP mono-(2-ethyl-5-hydroxyhexyl) phthalate, MEHP mono-2-ethylhexyl phthalate, MEOHP mono-(2-ethyl-5-
oxohexyl) phthalate, MEP monoethyl phthalate, MiBP monoisobutyl phthalate, MnBP mono-n-butyl phthalate, NA not applicable.
aDBP metabolite sum = MiBP+ MnBP; DEHP metabolite sum= MEHP + MEHHP +MEOHP + MECPP.
bSum of 8 phthalate metabolites.
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points for 28% of women. The percentage of women
with analyte levels in the lowest quartile at time 1 whose
levels were also in the lowest quartile at time 2 was 45%
for BPA and 30% for MEHP. Among women with ana-
lyte levels in the highest quartile at time 1, the percent-
age of women with analyte levels in the highest quartile
at time 2 was 25% for BPA and 20% for MEHP. The
weighted kappa statistic was 0.08 for both BPA and
MEHP (95% CIs =-0.08, 0.24 for BPA and -0.14, 0.30 for
MEHP) (Table 5). For MnBP, which had the highest
ICC, 45% of women were classified in the same quartile
at time 1 and time 2. Sixty percent of women with
MnBP levels in the lowest quartile at time 1, also had
MnBP levels in the lowest quartile at time 2. Among
women with MnBP levels in the highest quartile at
time 1, 50% had levels in the highest quartile at time 2
(weighted kappa= 0.40, 95% CI: 0.19, 0.61).
Discussion
We observed poor within-person stability of urinary BPA
over 1 to 3 years among NHS and NHSII participants, the
majority of whom donated first-morning urine samples.
Seven phthalate metabolites (MEP, MiBP, MnBP, MBzP,
MEHHP, MEOHP, MECPP) and PA demonstrated fair
or nearly fair within-person reproducibility over time.
Table 4 Within-person reproducibility of urinary bisphenol A, phthalate metabolites, and phthalic acid over 1–3 years
All samples First morning urine samples only
Analyte
a Spearman
correlation
Between-person
variation
Within-person
variation
Intraclass
correlation
(95% CI)
Spearman
correlation
Between-person
variation
Within-person
variation
Intraclass
correlation
(95% CI)
Bisphenol A 0.19 0.08 0.50 0.14 (0.03, 0.49) 0.23 0.09 0.53 0.15 (0.03, 0.54)
Phthalate metabolites
MEP 0.41 0.40 0.80 0.33 (0.13, 0.63) 0.53 0.48 0.61 0.44 (0.21, 0.70)
MiBP 0.47 0.31 0.72 0.30 (0.10, 0.62) 0.47 0.31 0.77 0.29 (0.08, 0.64)
MnBP 0.55 0.34 0.31 0.53 (0.31, 0.73) 0.44 0.29 0.35 0.45 (0.22, 0.71)
DBP sum
b 0.51 0.31 0.37 0.45 (0.23, 0.69) 0.40 0.26 0.43 0.38 (0.15, 0.67)
MBzP 0.43 0.32 0.64 0.33 (0.12, 0.63) 0.46 0.32 0.71 0.31 (0.11, 0.64)
MEHP 0.03 0.15 0.93 0.14 (0.01, 0.67) 0.08 0.18 0.94 0.16 (0.02, 0.68)
MEHHP 0.18 0.43 0.58 0.43 (0.21, 0.68) 0.21 0.48 0.58 0.45 (0.22, 0.70)
MEOHP 0.30 0.44 0.62 0.42 (0.20, 0.67) 0.41 0.50 0.59 0.46 (0.24, 0.70)
MECPP 0.20 0.29 0.46 0.39 (0.17, 0.66) 0.27 0.36 0.41 0.47 (0.24, 0.71)
DEHP sum
b 0.20 0.31 0.51 0.38 (0.16, 0.65) 0.30 0.35 0.49 0.42 (0.19, 0.68)
Total
c 0.39 0.27 0.41 0.40 (0.18, 0.66) 0.54 0.32 0.31 0.51 (0.28, 0.73)
Phthalic acid 0.41 0.11 0.15 0.41 (0.18, 0.69) 0.40 0.10 0.15 0.41 (0.16, 0.71)
Abbreviations: CI confidence interval, DBP dibutyl phthalates, DEHP di-2-ethylhexyl phthalate, ICC intraclass correlation coefficient, MBzP monobenzyl phthalate,
MECPP mono-(2-ethyl-5-carboxy-pentyl) phthalate, MEHHP mono-(2-ethyl-5-hydroxyhexyl) phthalate, MEHP mono-2-ethylhexyl phthalate, MEOHP mono-(2-ethyl-5-
oxohexyl) phthalate, MEP monoethyl phthalate, MiBP monoisobutyl phthalate, MnBP mono-n-butyl phthalate.
aAll values were adjusted for creatinine (pmol/mg creatinine) and natural log-transformed. Mean (range) time between collections was 2 (1–3) years.
bDBP sum= MiBP + MnBP; DEHP sum= MEHP + MEHHP+ MEOHP +MECPP.
cSum of 8 phthalate metabolites.
Table 5 Weighted Kappa statistics summarizing agreement
between analyte quartile categories determined at each
time point
Analyte Weighted Kappa statistic (95% CI)
Bisphenol A 0.08 (−0.08, 0.24)
Phthalate metabolite
MEP 0.28 (0.05, 0.51)
MiBP 0.24 (0.04, 0.44)
MnBP 0.40 (0.19, 0.61)
DBP metabolite sum
a 0.36 (0.14, 0.58)
MBzP 0.20 (−0.01, 0.41)
MEHP 0.08 (−0.14, 0.30)
MEHHP 0.08 (−0.16, 0.32)
MEOHP 0.20 (−0.03, 0.43)
MECPP 0.12 (−0.11, 0.35)
DEHP metabolite sum
a 0.12 (−0.10, 0.34)
Total
b 0.20 (−0.03, 0.43)
Phthalic acid 0.40 (0.14, 0.66)
Abbreviations: BzBP benzylbutyl phthalate, CI confidence interval, DBP dibutyl
phthalates, DEHP di-2-ethylhexyl phthalate, DEP diethyl phthalate, MBzP
monobenzyl phthalate, MECPP mono-(2-ethyl-5-carboxy-pentyl) phthalate,
MEHHP mono-(2-ethyl-5-hydroxyhexyl) phthalate, MEHP mono-2-ethylhexyl
phthalate, MEOHP mono-(2-ethyl-5-oxohexyl) phthalate, MEP monoethyl
phthalate, MiBP monoisobutyl phthalate, MnBP mono-n-butyl phthalate.
aDBP metabolite sum = MiBP+ MnBP; DEHP
metabolite sum = MEHP+ MEHHP+ MEOHP + MECPP.
bSum of 8 phthalate metabolites.
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Most, but not all [18-21], previous studies of within-
person reproducibility of urinary BPA and phthalate me-
tabolites examined stability over a period of 3 months or
less and in adults aged less than 60 years [16]. Regarding
urinary BPA, high intra-individual variation relative to
total variation has been found over 1 week among 8
adults aged 26–58 years (ICC =0.23 in first-morning
urine samples) [27] as well as over approximately
6 months among 389 pregnant women (ICC =0.1 in
spot urine samples) [19]. However, one study of 60
premenopausal women aged 21–42 years found moder-
ate reproducibility (ICC =0.43) of BPA measured in
first-morning urine samples over 4 weeks [28]. Similar
to our results, Braun et al. [20] calculated an ICC of 0.23
for repeated BPA measurements in pre-pregnancy spot
urine samples donated <1 week to over 2 years apart
(median 12 weeks apart) from 137 women aged 18–
45 years. Regarding urinary phthalate metabolites, our
ICC estimates for reproducibility of MEP, DBP metabo-
lites, MBzP, and MEHP over 1 to 3 years generally were
lower than those reported in studies examining reprodu-
cibility of these metabolites in men and non-pregnant
women over periods of 3 months or less [29-31]. How-
ever, our results for DBP metabolites, MBzP, and MEHP
were similar to those of Braun et al. [20], who analyzed
reproducibility in samples donated up to 110 weeks
apart. For example, Braun et al. reported ICCs ranging
from 0.35-0.40 for DBP metabolites and MBzP, and an
ICC of 0.11 for MEHP [20]. Interestingly, within-person
reproducibility over time of MEHHP, MEOHP, and
MECPP tended to be higher in our study than in shorter
duration studies, which found ICCs ranging from 0.13-
0.25 [21,30], or the longer-duration study by Braun
et al., which reported an ICC of 0.11 for the sum of
DEHP metabolites [20].
The half-lives of BPA and phthalate metabolites are
relatively short (<6 to 15 hours) [5,6]. Also, most women
in our study donated first-morning urine samples, which
likely reflect exposure the previous evening. Thus, habit-
ual exposure to sources of BPA and phthalates at about
the same time each day would likely be necessary
to observe reasonable within-person reproducibility in
our study. The moderate correlations we observed for
diethyl phthalate and dibutyl phthalates metabolites may
reflect habitual use of personal care products (primary
sources of diethyl phthalate and dibutyl phthalates [32]).
Likewise, diet generally follows a long-term consistent
pattern [33], possibly explaining moderate correlations
we observed for the primary metabolite of benzylbutyl
phthalate and secondary metabolites of DEHP, which
may contaminate foods via the soil [34] as well as during
processing and storage [3]. The primary metabolite of
DEHP, MEHP, has the shortest half-life of the DEHP me-
tabolites (5 hours [5]) and is mostly converted to the
secondary metabolites via oxidative metabolism [1],
which may explain its poor long-term reproducibility.
PA, a non-specific phthalate metabolite, was moderately
reproducible within women over time, reflecting the
moderate correlations observed for the majority of
phthalate metabolites.
Food packaged in polycarbonate or epoxy-lined
containers is a primary source of BPA exposure [1]. Yet,
unlike metabolites of benzylbutyl phthalate and DEHP,
which are also found mainly in foods, we observed poor
within-person stability of BPA over 1 to 3 years. The
reason for this discrepancy is unclear, however, there are
many potential sources of human exposure to BPA [2]
and variability in non-food sources (e.g., handling of
thermal receipts) may contribute to poor within-person
reproducibility over time.
Several limitations of our study should be considered.
First, variation in analyte levels due to delayed process-
ing of urine samples and laboratory variability is incor-
porated into the ICCs. However, previous studies
demonstrated excellent stability of BPA and phthalate
metabolites in urine samples stored at room temperature
up to 2 days, and coefficients of variation for most
analytes were ≤15%, suggesting that ICCs were not sub-
stantially affected by these sources of error [35,36]. In
addition, the number of women included in our studies,
particularly the phthalate metabolite and PA studies,
was relatively small (N =33-80), which contributed to
wide CIs for the ICC estimates; thus it is important
that these results are interpreted cautiously. Finally,
our estimates of long-term reproducibility of BPA
and phthalate metabolites in spot urine samples are
specific to NHS and NHSII participants and may not
be generalizable to other populations with different
exposure patterns.
Conclusions
Overall, our observation of low reproducibility of urinary
BPA excretion over 1 to 3 years indicates evaluation of
associations with disease risk in epidemiologic studies
may be challenging when only a single spot urine meas-
urement is available. Indeed, according to the Spearman-
Brown prophecy formula [37], our ICC estimate for BPA
suggests approximately 5 spot measurements would be
required to achieve a fair ICC of 0.4. Single measure-
ments of certain phthalate metabolites and PA may be
acceptable for prospective epidemiologic studies of dis-
eases with long latency periods. Since within-person cor-
relations were moderate, biomarker-disease associations
will likely be attenuated and measurement error correc-
tion techniques may be necessary to understand the full
magnitude of the impact of phthalates on health.
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